GT-00A x IL15 / Glycotope - LARVOL DELTA

GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies. (PubMed, Int J Mol Sci) - "These results support the rationale to improve PK and anti-tumor efficacy of IL-15 by increasing local concentrations at the tumor site via conjugation to a TA-MUC1 binding mAb. The tumor-selective expression pattern of TA-MUC1, powerful immune activation and anti-tumor cytotoxicity, long serum half-life and tumor targeting properties, render GT-00AxIL15 a promising candidate for treatment of solid tumors with high medical need, e.g., ovarian, lung and breast cancer."

Journal • PK/PD data • Preclinical • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD8 • IL15 • MUC1

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer (GlobeNewswire) - "Therabest USA. Inc...and Glycotope GmbH...have signed an agreement to assess the clinical development of Therabest’s EiNKTM (Enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK cell therapies from various cell sources have demonstrated exciting results in early clinical trials and are rapidly becoming powerful alternatives to conventional treatments. However, for solid tumors, NK cell therapies are still hampered by the low persistency and homing of NK cells. The combination of Therabest’s iPSC derived NK cell therapy TB-100 and Glycotope’s tumor-targeted immuno-cytokine GT-00AxIL15 challenges the current NK cell therapy paradigm by converging a two-component platform in which the dosage of an immuno-cytokine improves the activity of TB-100."

Licensing / partnership • Breast Cancer • Oncology • Triple Negative Breast Cancer

Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties (AACR 2022) - "Our results show that by using TA-MUC1 as a broadly expressed and highly tumor-specific antigen, we are able to direct IL-15 to the tumor. Local enrichment of GT-00A x IL15 within the tumor ultimately induced local effector cell activation and expansion. GT-00A x IL15 showed single agent efficacy in vivo with a good safety profile."

Preclinical • Oncology • Solid Tumor • CD8 • IL15 • MUC1

Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting (GlobeNewswire) - "Glycotope GmbH...announces that it will present new data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, United States, between 8-16 April 2022....'The data presented at AACR shows the potential of targeting GlycoTargets to increase the tumor-selectivity of antibodies. We will present two anti-GlycoTarget antibodies with markedly improved tumor-selectivity compared to protein binding antibodies resulting in reduced binding to healthy tissues or blood cells. Additionally, we will present updated in vivo efficacy data for GT-00A x IL15, our TA-MUC1-targeting IL-15 fusion antibody.'"

Preclinical • Oncology • Solid Tumor

Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties (SITC 2021) - "GT-00A x IL15 shows increased accumulation in the tumor and mediates enhanced cytotoxicity and immune cell infiltration compared to an untargeted IL-15 control construct highlighting the potential to increase the efficacy and safety of IL-15-based immunocytokines by tumor targeting. GT-00A x IL15 shows great promise for the treatment of TA-MUC1-positive solid tumors either as monotherapeutic agent or as valuable combination partner."

Preclinical • Oncology • Solid Tumor • CD8 • IL15 • MUC1